TRS01 / Tarsius Pharma - LARVOL DELTA

Dazdotuftide: A New Steroid-Free Treatment for Noninfectious Anterior Uveitis With a Superior IOP Safety Profile (AAO 2024) - "Further, among subjects who reached ACC = 0 at Day 28, TRS01-treated subjects benefited from statistically significantly improved outcomes for each IOP endpoint (including change from baseline and at each IOP threshold evaluated [P < .05]) versus steroid-treated subjects. Conclusion TRS01 offers the potential to serve as an effective and safe treatment in uveitis that meets the urgent need for a drug that resolves inflammation without the associated risks of IOP elevation and glaucoma."

Clinical • Glaucoma • Ocular Inflammation • Ophthalmology • Uveitis

A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma (clinicaltrials.gov) - P3 | N=142 | Completed | Sponsor: Tarsier Pharma | Active, not recruiting ➔ Completed

Trial completion • Glaucoma • Ocular Inflammation • Ophthalmology • Uveitis

A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma (clinicaltrials.gov) - P3 | N=162 | Active, not recruiting | Sponsor: Tarsier Pharma | Recruiting ➔ Active, not recruiting

Enrollment closed • Glaucoma • Ocular Inflammation • Ophthalmology • Uveitis

A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma (clinicaltrials.gov) - P3 | N=162 | Recruiting | Sponsor: Tarsier Pharma | Trial completion date: Jan 2023 ➔ Apr 2023 | Trial primary completion date: Jan 2023 ➔ Apr 2023

Trial completion date • Trial primary completion date • Glaucoma • Ocular Inflammation • Ophthalmology • Uveitis

"Trst01 and Rubix Partner to Accelerate Climate Action Through Green Blockchain Platforms https://t.co/GS5Nn2ZOv0" (@NewsFromBW)

TRS01, a Novel Nonsteroidal Treatment of Active Noninfectious Anterior Uveitis: Results of a Phase 1/2 clinical trial (AAO 2021) - "71.4% of subjects in the 1% group reached zero cells on Week 3 and 4. Conclusion Results indicate preliminary safety and efficacy of TRS01 in resolution of anterior uveitis, to be confirmed in Phase 3 trials."

Clinical • P1/2 data • Ocular Inflammation • Ophthalmology • Uveitis

A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma (clinicaltrials.gov) - P3; N=162; Recruiting; Sponsor: Tarsier Pharma; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Glaucoma • Ocular Inflammation • Ophthalmology • Uveitis

A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma (clinicaltrials.gov) - P3; N=162; Not yet recruiting; Sponsor: Tarsier Pharma

Clinical • New P3 trial • Glaucoma • Ocular Inflammation • Ophthalmology • Uveitis

A Study to Evaluate TRS01 Eye Drops in Participants With Active Non-infectious Anterior Uveitis (clinicaltrials.gov) - P1/2; N=16; Completed; Sponsor: Tarsius Pharma; Active, not recruiting ➔ Completed; N=10 ➔ 16; Trial completion date: Feb 2021 ➔ Aug 2020; Trial primary completion date: Feb 2021 ➔ Aug 2020

Clinical • Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Complement-mediated Rare Disorders • Ocular Inflammation • Ophthalmology • Uveitis

A Study of TRS01 in Participants With Post-surgical Ocular Inflammation (clinicaltrials.gov) - P1/2; N=37; Completed; Sponsor: Tarsius Pharma; Active, not recruiting ➔ Completed; N=60 ➔ 37; Trial completion date: Feb 2021 ➔ Jul 2020; Trial primary completion date: Feb 2021 ➔ Jul 2020

Clinical • Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Cataract • Immunology • Inflammation • Ocular Inflammation

A Study to Evaluate TRS01 Eye Drops in Participants With Active Non-infectious Anterior Uveitis (clinicaltrials.gov) - P1/2; N=10; Active, not recruiting; Sponsor: Tarsius Pharma; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Complement-mediated Rare Disorders • Ocular Inflammation • Ophthalmology • Uveitis

A Study of TRS01 in Participants With Post-surgical Ocular Inflammation (clinicaltrials.gov) - P1/2; N=60; Active, not recruiting; Sponsor: Tarsius Pharma; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Cataract • Immunology • Ocular Inflammation

A Study of TRS01 in Participants With Post-surgical Ocular Inflammation (clinicaltrials.gov) - P1/2; N=60; Recruiting; Sponsor: Tarsius Pharma; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

A Study to Evaluate TRS01 Eye Drops in Participants With Active Non-infectious Anterior Uveitis (clinicaltrials.gov) - P1/2; N=10; Recruiting; Sponsor: Tarsius Pharma; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

A Study of TRS01 in Participants With Post-surgical Ocular Inflammation (clinicaltrials.gov) - P1/2; N=60; Not yet recruiting; Sponsor: Tarsius Pharma

Clinical • New P1/2 trial

A Study to Evaluate TRS01 Eye Drops in Participants With Active Non-infectious Anterior Uveitis (clinicaltrials.gov) - P1/2; N=10; Not yet recruiting; Sponsor: Tarsius Pharma

Clinical • New P1/2 trial